JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Listă Acțiuni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

38.99 -0.1

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

38.75

Maxim

39.11

Indicatori cheie
By Trading Economics
Venit	7.3M -123M
Vânzări	3.7M 3.9M
EPS	-1.29
Marjă de profit	-3,161.261
Angajați	594
EBITDA	20M -122M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+109.53% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-445M 4B
Deschiderea anterioară	39.09
Închiderea anterioară	38.99

Sentimentul știrilor

By Acuity

50%

180 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

30.39 / 33.46 Suport & Rezistență

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 mai 2026, 23:43 UTC

Evenimente importante

New Zealand's Unemployment Rate Falls in 1Q

5 mai 2026, 23:20 UTC

Acțiuni populare

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mai 2026, 21:48 UTC

Câștiguri

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mai 2026, 21:05 UTC

Achiziții, Fuziuni, Preluări

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mai 2026, 22:08 UTC

Câștiguri

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mai 2026, 22:07 UTC

Câștiguri

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mai 2026, 21:48 UTC

Câștiguri

Pan American Silver 1Q Rev $1.2B >PAAS

5 mai 2026, 21:42 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:38 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:30 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:29 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:26 UTC

Câștiguri

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mai 2026, 21:25 UTC

Câștiguri

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mai 2026, 21:24 UTC

Câștiguri

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mai 2026, 21:18 UTC

Câștiguri

Mistras Backs 2026 Rev $730M-$750M >MG

5 mai 2026, 21:17 UTC

Câștiguri

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mai 2026, 21:15 UTC

Câștiguri

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mai 2026, 21:12 UTC

Câștiguri

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mai 2026, 21:11 UTC

Câștiguri

SSR Mining 1Q Rev $581.8M >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mai 2026, 21:10 UTC

Câștiguri

SSR Mining 1Q EPS $1.16 >SSRM

5 mai 2026, 21:08 UTC

Câștiguri

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mai 2026, 21:01 UTC

Câștiguri

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mai 2026, 21:01 UTC

Acțiuni populare

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

109.53% sus

Prognoză pe 12 luni

Medie 86.43 USD 109.53%

Maxim 97 USD

Minim 67 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Crinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

180 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.